Drug information for patients - Unmet needs, evaluation and influence on the compliance;Arzneimittelberatung für Patienten - Bedarfsanalyse, evaluation und einfluss auf die compliance

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 24, 2005, Pages 1485-1490

  Maywald, Ulf ^a   Schindler, C ^a   Bux, Y ^a   Kirch, W ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; CERIVASTATIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SEX HORMONE;

ADULT; AGED; AMBULATORY CARE; ARTICLE; COMPETENCE; DOCTOR PATIENT RELATION; DRUG INFORMATION; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT EDUCATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; DRUG INFORMATION SERVICES; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICIAN-PATIENT RELATIONS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 21444436143     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870843     Document Type: Article

References (30)

1. Anderson JG, Rainey MR, Eysenbach M. The impact of cyberhealthcare on the physician-patient relationship. J Med Systems 2003; 27: 67-84
2. Bader SA, Braude RM. "Patient informatics": Cerating new partnerships in medical decision making. Acad Med Approach 1998; 73: 408-411
3. Balint J, Shelton W. Regaining the initiative. Forging a new model of the patient-physician relationship. JAMA 1996; 275: 887-891
4. Bartlett EE, Cost-benefit analysis of patient education. Patient education and counseling 1996; 26: 87-91
5. Bendtsen P. Pharmacological intervention in older patients with rheumatoid arthritis. Quality of life aspects. Drugs & Aging 1995; 7: 338-346
6. Bonelli RM, Thau K. Noncompliance - ein Überblick. Dtsch Med Wochenschr 2001; 126: 699-703
7. Coambs R. Review of the scientific literature on the prevalence, consequences, and health costs of noncompliance & inappropriate use of prescription medication in canada. Toronto: University of Toronto Press, 1995: 89-97
8. Deveugele M, Derese A, van den Brink-Muinen A, Bensing J, De Maeseneer J. Consultation length in general practice: cross sectional study in six European countries. Brit Med J 2002; 325: 472-478
9. Donabedian A. The quality of care. How can it be assessed? JAMA 1988; 260: 1743-1748
10. Ferris D, Menyah DK. Reducing the use of inappropriate medications in the hospitalized elderly. Am J Health Syst Pharm 2001; 58: 1588-1592
11. Gautier S, Bachelet H, Bordet R, Caron J. The cost of adverse drug reactions. Expert Opin Pharmacother 2003; 4: 319-326
12. Grymonpre RE, Steele JW. The medication information line for the elderly: an 8-year cumulative analysis. Ann Pharmacother 1998; 32: 743-748
13. Krause P, Wittchen H-U, Küpper B et al. Wie beurteilen Primärärzte ihre Versorgungspraxis bei Diabetes mellitus und arterieller Hypertonie? FortschrMed (Sonderheft I) 2003; 120: 12-18
14. McMahon T, Clark CM, Bailie GR. Who provides patients with drug information? Brit Med J 1987; 294: 355-356
15. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge, recommendations for a call to action: A statement for healthcare professionals. Circulation 1997; 95: 1085-1090
16. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997; 10: 697-704
17. O'Brien MK, Petrie K, Raeburn J. Adherence to medication regimens: updating a complex medical issue. Med Care Rev 1992; 49: 435-454
18. Roe CM, McNamara AM, Motheral BR. Gender- and age-related prescription drug use patterns. Ann Pharmacother 2002; 36: 30-39
19. Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen. Bedarfsgerechtigkeit und Wirtschaftlichkeit. Band 1: Zielbildung, Prävention, Nutzerorientierung und Partizipation. Bonn, 2001
20. Schneider PJ, Gift MG, Lee YP et al. Cost of medication-related problems at a university hospital. Am J Health Syst Pharm 1995; 52: 2415-2418
21. Schwabe U, Paffrath D. Arzneiverordnungsreport 2002. Berlin: Springer Verlag, 2003
22. Schwarz UI, Krappweis J, Stoelben S, Kirch W. Drug information services: initial experiences in Dresden. Eur J Clin Pharmacol 1998; 54: 667-668
23. Smith GH, Einarson TR. Survey of consumer users of a statewide drug information service. Am J Hosp Pharm 1985; 42: 1557-1561
24. Spinewine A, Dean B. Measuring the impact of medicines information services on patient care: methodological considerations. Pharm World Sci 2002; 24: 177-181
25. Statistisches Landesamt Sachsen. Bevölkerung am 31. Dezember 1990 bis 2000. Statistisches Landesamt Sachsen. Online aufgerufen am 13.01.2005. URL: http://www.statistik.sachsen.de/lnhalt/44fachstat/bevoelkerung/datentabellen/ Sachsen.pdf, 2003
26. Sturdee DW. The importance of patient education in improving compliance. Climacteric 2000; 3: 9-13
27. Volmer T, Kielhorn A. Kosten der Non-Compliance. Gesund ökon Qual manag 1999; 4: 55-61
28. World Health Organization. Declaration of Alma-Ata. Online aufgerufen am 13.01.2005. URL: http://www.who.int/hpr/archive/docs/almaata.html, 1978
29. World Health Organization. Essential Drugs and Medicines Policy: Rational Drug Use by Consumers. Online aufgerufen am 13.01.2005. URL: http://www.who.int/medicines/strategy/rationa_use/strudons.shtml, 2002
30. Melnyk PS, Shevchuk YM, Remillard AJ. Impact of the dial access drug information service on patient outcome. Ann Pharmacother 2000; 34:585-92